METHOD FOR THE PROGNOSIS OF BREAST CANCER BASED ON THE EXPRESSION MARKERS
Method for the prognosis of breast cancer based on the expression of the prolyl isomerase enzyme Pin1 combined with the detection of mutations in the TP53 gene

Brief description
The invention relates to a prognostic method for breast tumors based on the expression of the prolyl isomerase enzyme Pin1 combined with detection of the presence of missense mutations in the TP53 gene and in particular to a molecular signature produced by the characteristics 10-gene expression associated with the Pin1 mutant p53 axis. The invention has also a kit for the method implementation.

Innovative aspects and main advantages
The methodology of the invention allows to stratify the patients with tumor ER+ (oestrogen-positive), due to the detection of the presence of missense mutations in the TP53 associated with the Pin1. The main advantage concerns the utilization of a better therapy than the one in use. The invention may lead to a more efficient identification of the patients who could benefit the combination of hormone treatment and chemotherapy.

Applications
The method can be employed to prevent breast tumors. The use of the molecular signature in a computer implemented method can be applied to patients with oestrogene-positive tumours.

Potential market
Our potential target market refers to preventive medicine, in particular the utilization of the method aims at preventing breast tumors.

Development status
Laboratory tests.

Category:
Life Sciences
Patent Ownership:
UNIVERSITA’ DI TRIESTE, UNIVERSITY OF DUNDEE
Inventor:
Giannino DEL SAL, Marco NAPOLI, Javier Enrique GIRARDINI BROVELLI, Silvano PIAZZA, Thompson ALASTAIR
Priority:
16/06/2011
Patent Number:
IT1406393 EP2721178
Patent Status:
Granted in France, Germany, Great Britain, Switzerland and Italy
Licensing Availability:
Available
Contacts:
ILO e PLACEMENT
E-mail: ilo@units.it Tel: + 39 040 558 3012